Tolera Therapeutics, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tolera Therapeutics, Inc.
Celiac Research Partnership Builds Takeda’s GI Interests
Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.
Start-Up Execs On The Move, November 2012
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Recent Financings of Private Companies, November 2012
START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Laureate signs antibody deal with Tolera
Laureate Pharma has signed a contract manufacturing agreement for Tolera Therapeutics' TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. TOL101 has demonstrated safety and efficacy in Phase I and II trails for treating episodes of rejection or as a means of preventing rejection in kidney and other solid organ transplants. Laureate, a biopharmaceutical development and protein production company, and Tolera, a biotechnology company, are both based in the US.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice